FCM
BIIB icon

Fieldview Capital Management’s Biogen BIIB Stock Holding History

Fieldview Capital Management’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$270K Sell
1,250
-16,409
-93% -$3.14M 0.08% 408
2026
Q1 		$3.24M Buy
17,659
+3,387
+24% +$624K 0.95% 3
2025
Q4 		$2.51M Buy
+14,272
New +$2.33M 0.43% 72
2025
Q3 		– Sell
-8,837
Closed -$1.11M – 398
2025
Q2 		$1.11M Buy
+8,837
New +$1.1M 0.17% 176

Other funds holding BIIB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Fieldview Capital Management's BIIB Position: Q2 2026 in Review

Fieldview Capital Management reduced its Biogen (BIIB) stake by 93% in Q2 2026, selling an estimated $3.14M and leaving 1,250 shares worth $270K. The position accounts for 0.08% of the portfolio, ranked #408.

Fieldview Capital Management first reported a position in BIIB in Q2 2025 and has held it in 4 quarters since. The position peaked at $3.24M in Q1 2026. 1,043 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.

  • Fieldview Capital Management held 1,250 shares of Biogen worth $270K as of Q2 2026.
  • Fieldview Capital Management sold 16,409 Biogen shares in Q2 2026, an estimated $3.14M.
  • Biogen made up 0.08% of Fieldview Capital Management's portfolio in Q2 2026, its #408 holding.
  • Fieldview Capital Management first reported a position in Biogen in Q2 2025 and has held it in 4 quarters since.
  • Fieldview Capital Management's Biogen position peaked at $3.24M in Q1 2026.
  • 1,043 funds tracked by Wall St. Rank held Biogen as of Q2 2026.

Based on Fieldview Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.